Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.